ClinicalTrials.gg
CompletedNCT00080444Updated Aug 5, 2014

Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

A Phase 3 interventional study of aprepitant and ondansetron in Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-08-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.

Enrollment
39th of 61
50 · median 92
Started
2004
with 2 others
Phase 3
15 of 61
1 open now
Registered
1st of 61
by date
Lead sponsor
9 of 61
Merck Sharp & Dohme LLC

Among the 61 studies testing aprepitant in Vomiting, this one is the 39th largest by enrollment, is one of 3 that started in 2004, is one of 15 in phase 3, and was the 1st registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing aprepitant in Vomiting, or all of them as a file.
02

Study summary

This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants. Participants treated with emetogenic cancer chemotherapies that include either cisplatin, cyclophosphamide, or carboplatin, or participants who experienced nausea and/or vomiting when treated with a previously administered chemotherapy regimen that is planned to be repeated will be enrolled in this study. In the double-blind Part 1 of this study, enrolled participants will be randomized to receive either aprepitant or standard therapy. In Part 2 of this study, enrolled participants will receive open-label aprepitant.

Read the detailed description

The duration of treatment is the first 4 days of one 28-day cycle (Cycle 1). Participants who successfully complete Cycle 1 may be eligible to participate for 9 subsequent optional, open-label, 28-day cycles.

03

Conditions studied

  • Vomiting

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cycle 1: Participant is to be treated with an emetogenic chemotherapy regimen that includes either cisplatin, cyclophosphamide, or carboplatin, for a documented . OR Participant did not tolerate a previously administered chemotherapy regimen, for a documented malignancy, secondary to nausea and/or vomiting that is planned to be repeated.
  • Cycle 1: Participant has score ≥60
  • Cycle 1: Participant has a predicted of ≥3 months

Exclusion criteria

Exclusion Criteria:

  • Cycle 1: Participant will receive stem cell rescue therapy in conjunction with course of chemotherapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Part 1: Aprepitant

    Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.

    Drug: aprepitant · Drug: ondansetron · Drug: dexamethasone · Drug: placebo to dexamethasone · Drug: rescue medication

  • Active comparator
    Part 1: Standard Therapy

    Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.

    Drug: ondansetron · Drug: dexamethasone · Drug: placebo to aprepitant · Drug: rescue medication

  • Active comparator
    Part 2: Aprepitant

    Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.

    Drug: aprepitant · Drug: ondansetron · Drug: dexamethasone · Drug: placebo to dexamethasone · Drug: rescue medication

Interventions

  • aprepitant capsules

  • ondansetron IV preparation

  • dexamethasone tablets

  • Drugplacebo to aprepitant

    Matching placebo to aprepitant capsules

  • Drugplacebo to dexamethasone

    Matching placebo to dexamethasone tablets

  • Drugrescue medication

    Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycle 1)

    Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)

Secondary outcomes

  1. Percentage of Participants Who Experience a Complete Response (CR) to Anti-emetic Therapy (Cycle 1)

    Time frame: Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1

  2. Percentage of Participants Who Experience Absence of Nausea (Cycle 1)

    Time frame: Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1

  3. Percentage of Participants Who Experience Absence of Vomiting (Cycle 1)

    Time frame: Up to 120 hours after initiation of emetogenic chemotherapy in Cycle 1

  4. Percentage of Participants Who Experience Serious Adverse Events (Cycles 2-10)

    Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycles 2-10 (Up to 10.5 months)

  5. Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycles 2-10)

    Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycles 2-10 (Up to 10.5 months)

  6. Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycles 2-10)

    Time frame: Up to Day 4 of Cycles 2-10 (Up to 10 months)

  7. Percentage of Participants Who Experience Serious Adverse Events (Cycle 1)

    Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)

  8. Percentage of Participants Who Experience Serious Study-drug-related Adverse Events (Cycle 1)

    Time frame: Up to 14 days after last dose of anti-emetic therapy in Cycle 1 (Up to 18 days)

  9. Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycle 1)

    Time frame: Up to Day 4 of Cycle 1

  10. Aprepitant Plasma Drug Concentration Profiles and Pharmacokinetics

    Time frame: Up to 24 hours after first dose of aprepitant

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B; Adolescent Aprepitant in Cancer Study Group. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009 Feb;52(2):242-7. doi: 10.1002/pbc.21811. PubMed 18985740 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Sep 2006 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2004
First posted
Apr 2, 2004
Start
Apr 2004
Primary completionActual
Sep 2006
CompletionActual
Mar 2007
Last update
Aug 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00080444
Responsible party
Sponsor
First posted
Apr 2, 2004
Start date
Apr 2004
Primary completion
Sep 2006
Completion
Mar 2007
Last update
Aug 5, 2014

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprepitant

Start the discussion